|Day Low/High||46.20 / 49.25|
|52 Wk Low/High||42.19 / 125.00|
The real reason the stock may be popping after the CEO news.
Intercept says it received approval from the FDA.
We're in the middle of earnings season, and that means big moves for individual names. All the following companies are on the move prior to today's opening bell: Nvidia is the big story today after reporting strong earnings after the close. The stoc...
But we could see more volatility in the market.
Investors seeking to bet against Tesla's common stock may want to give its convertible bonds a spin.
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
The broad market remains pretty flat this afternoon after giving up its solid early gains. Biotech is also taking a rest from its huge rally since March 30, giving back a bit more than 1% so far today. However, there's some interesting action on Int...
TheStreet's Gregg Greenberg has the list of the Wall Street shenanigans you may have missed this week.
I will take an unbalanced butterfly approach with a cost very close to zero.
I've been pleasantly surprised by my conversations with folks at my recent book signings.
Quietly, the IPO market is back. The number of deals peaked at 214 in 2007, plunging to only 31 in 2008, but climbed back to 128 in 2012. Those deals raised $42.6 billion, a touch below the $49 billion raised in 2007. Forty-four were private-equity-...
Francis Gaskins, president of IPO Desktop, says he's going to sit on the sidelines with KYTHERA and Intercept.